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A B S T R A C T
Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease of the central nervous system, char-
acterized by progressive loss of motor neurons, and occurring in both sporadic and familial form. The origin of
the disease is unknown, though increasing evidence suggests that the interaction between genetic and en-
vironmental factors may increase susceptibility to ALS, including its sporadic form. Although genetic mutations
have been correlated to the familial type of ALS, relatively little is known about the sporadic type (sALS). Genetic
factors concerning pesticide metabolism and heavy metal detoxification are increasing the susceptibility to sALS.
This review focuses on the genes implicated in metabolic detoxification pathways of environmental toxicants
and their potential role in ALS susceptibility.
1. Introduction
Amyotrophic lateral sclerosis (ALS) is a heterogeneous group of
neurodegenerative disorders (Hardiman et al., 2017; Sabatelli et al.,
2016). It is considered to be the third most common neurodegenerative
disease and the most frequent form of motor neuron disease with onset
in the adulthood (Renton et al., 2014). ALS is characterized by pro-
gressive loss of motor neurons and rapidly progressive paralysis (Appel
et al., 2011). It remains a very serious health problem, as within 2 to
3 years after the first symptoms, respiratory failure leads to death
(Rowland and Shneider, 2001). Despite the fact that the cause of ALS
still remains unknown, accumulative evidence suggests that genetic and
environmental factors may be involved and interact to increase the
susceptibility to ALS development (Peters et al., 2015; Zarei et al.,
2015).
At genetic level, ALS can be classified into familial ALS (fALS),
which constitutes approximately 10% of all ALS cases and sporadic ALS
(sALS), with no evident genetic linkage, which accounts for 90% of all
ALS cases (Chen et al., 2013). Genetic mutations were found to be re-
sponsible for fALS under autosomal dominant, autosomal recessive or
X-linked mode of inheritance (Chen et al., 2013; Renton et al., 2014;
Taylor et al., 2016). Recently, a considerable effort has been made in
order to elucidate the genetic susceptibility of sALS. Candidate gene
association studies (CGASs) and genome-wide association studies
(GWASs) have led to the identification of several genetic loci that may
modify the risk of sALS (Chen et al., 2013; Mitropoulos et al., 2017;
Nicolas et al., 2018; Renton et al., 2014).
Quite a few exogenous factors such as smoking, antioxidants, phy-
sical exercise & fitness, body mass index, electromagnetic fields, head
trauma, metabolic and inflammatory diseases, viral infections, metals
and pesticide exposure have been incriminated for possible contribu-
tion to ALS development (Ingre et al., 2015; Su et al., 2016; Vinceti
et al., 2012). There is evidence that polymorphisms may modify the
effect of environmental exposures to the risk of disease development
(Kelada et al., 2003). The interplay between genetic and environmental
factors and epigenetic modifications may have an impact on ALS sus-
ceptibility (Al-Chalabi and Hardiman, 2013; Paez-Colasante et al.,
2015; Zarei et al., 2015; Zufiria et al., 2016). A few studies, with a
variety in design (case-control, cohort, perspective, meta-analysis and
systematic reviews) have demonstrated an association between ALS and
pesticides, heavy metals, mercury and xenobiotics (Bozzoni et al., 2016;
Capozzella et al., 2014; Deziel et al., 2015; Gibb and O'Leary, 2014;
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Krewski et al., 2017; Yu et al., 2014). However, there are also studies
that have failed to reveal any association (Capozzella et al., 2014;
Vinceti et al., 2017a; Vinceti et al., 2017b; Yu et al., 2014). The review
by Bozzoni et al. concluded that there is strong evidence that pesticides
have a crucial role in ALS development and that they are significant risk
factors for neurodegeneration (Bozzoni et al., 2016). In contrast, the
meta-analysis by Capozzela et al. has failed to prove a strong correla-
tion between exposure to pesticides and ALS risk, as only a mild asso-
ciation was revealed (Capozzella et al., 2014). Moreover, Kamel et al.
have indicated that ALS risk may depend on the kind of the pesticide
(Kamel et al., 2012). There is also accumulative body of epidemiologic
evidence that long-term pesticide exposure (even in low doses) pre-
disposes to several neurodegenerative diseases (Baltazar et al., 2014;
Zaganas et al., 2013). Long term exposure to organochlorine and to
organophosphate pesticides may have a crucial role in Motor neuron
Disease development (Kanavouras et al., 2011). Regarding the role of
heavy metals (selenium, mercury, cadmium and iron) in ALS, despite
the large number of studies, only a few of them have revealed an as-
sociation (Bozzoni et al., 2016; Trojsi et al., 2013; Vinceti et al., 2014).
Additionally, both xenobiotic metabolism pathways and genetic varia-
tion, which affects xenobiotic metabolism, may confer susceptibility to
ALS (Kasperaviciute et al., 2007).
It is possible that the divergence in findings regarding the effects of
pesticide exposure, heavy metals and xenobiotic metabolism on ALS
risk may result from the genetic variability among the studied popu-
lations. Pesticide to gene interaction has been demonstrated by genetic
association studies as well as by animal models (Dardiotis et al.,
2013b). The aim of the present review is to discuss the current
knowledge by focusing on genes that predispose to ALS development
and are probably implicated in toxicity mechanisms and detoxification
metabolic pathways of environmental toxicants.
2. Methods-study identification and selection
We searched PubMed for peer-reviewed articles, published in
English language through December 2017, concerning human studies
on ALS and polymorphisms across genes that are implicated to detox-
ification pathways of environmental toxicants. Our search included
“amyotrophic lateral sclerosis” and “polymorphisms”, in combination
with the following terms: “pesticides”, “lead”, “heavy metals”, “iron”,
“toxicity” and “oxidative stress”, as free words. Last literature search
was performed on December 31st, 2017. Additionally, reference lists of
all retrieved articles were examined in order to identify studies missing
from our initial database search. Published studies (case-control can-
didate gene association studies, gene-environment studies, meta-ana-
lyses, genome wide association studies, mutational screenings, cases
only studies) between 1996 and 2016 were included. Baseline char-
acteristics from studies regarding PON1, PON2 and PON3 genes are
summarized in Table 1. Baseline characteristics from studies regarding
ALAD, VDR, SNCA, MT family genes, MTF-1, GSS, FMO, SOD1, HFE,
PGC-1α, Nrf2, Transferrin, GSTs, ACHE, BCHE, NTE, FAH, CNR1, AA-
DACL1, AFMID, APEH, CYP1A, CYP1B1, CYP2B6, CYP2C, CYP2D6,
CYP2E1 and CYP3A are presented in Table 2.
3. Results & discussion
3.1. PON1, PON2 and PON3
Paraoxonase-1 gene: Paraoxonase-1 (PON1) is a serum calcium de-
pendent esterase enzyme that is synthesized primarily in the liver and
carried by high density lipoproteins (HDLs) (Costa et al., 2013). Its
main function is to catalyze hydrolysis of the active metabolites (oxons)
of some organophosphates including parathion, diazinon and chlor-
pyrifos (Costa et al., 2013). Hydrolysis of these products leads to the
metabolites: diethylphosphate (DEP), trichloropyridinol (TCP), me-
thylpyrimidinol (MHP) and para-nitrophenol (PNP) (Androutsopoulos
et al., 2011). Variants across PON1 gene have been reported to influ-
ence the concentration of paraoxonase-1 enzyme in serum, the protein
stability and/or its catalytic activity (Dardiotis et al., 2013b). Rs662
(Q192R) and rs854560 (L55M) are non-synonymous functional coding
polymorphisms that affect PON1 expression, catalytic function and
plasma levels (Adkins et al., 1993; Androutsopoulos et al., 2011;
Dardiotis et al., 2013b). The isoform with arginine (R) at 192 breaks
down paraoxon, while the isoform with glutamine (Q) at 192 is more
efficient in breaking down sarin, diazozon and soman (Adkins et al.,
1993; Androutsopoulos et al., 2011; Dardiotis et al., 2013b; Morahan
et al., 2007b). The other functional polymorphism rs854560 (L55M)
influences PON1 plasma levels (Adkins et al., 1993; Androutsopoulos
et al., 2011; Dardiotis et al., 2013b; Morahan et al., 2007b). More
precisely, individuals with methionine (M) at the position 55 reveal
decreased expression, lower levels and reduced activity of PON1
(Adkins et al., 1993; Androutsopoulos et al., 2011; Dardiotis et al.,
2013b; Morahan et al., 2007b). The 3D model of the PON1 normal and
mutant proteins [resulting from rs662 (Q192R) and rs854560 (L55M)]
based on SWISS-MODEL protein structure software (http://swissmodel.
expasy.org/) and the main pathophysiology of the hydrolysis of chlor-
pyrifos-oxon, paraoxon and diazoxon by PON1 to DEP and other sec-
ondary metabolites are depicted in Fig. 1.
Rs662 (Q192R) and rs854560 (L55M) SNPs have also been asso-
ciated with other neurodegenerative diseases, such as Alzheimer's dis-
ease (AD), Parkinson's disease (PD) and multiple sclerosis (MS) (Menini
and Gugliucci, 2014). A recent meta-analysis also provides strong evi-
dence that the PON1 rs705379 is associated with the risk of AD (Nie
et al., 2017). However, the results of case-control studies and meta-
analyses remain conflicting (Lee et al., 2015; Liu et al., 2012; Menini
and Gugliucci, 2014; Pi et al., 2012; Wills et al., 2009; Zintzaras and
Hadjigeorgiou, 2004). L55M and Q192R variants have been found to
increase the risk of organophosphate toxicity in a population-dependent
manner (You et al., 2013). Moreover, decreased PON1 activity has been
associated with I102V PON1 polymorphism as well as with the risk
alleles of the promoter polymorphisms rs705379 (−108T > C) and
rs705381 (−162G > A) across the 5′ regulatory-region (Brophy et al.,
2001; Cronin et al., 2007; Marchesani et al., 2003; Morahan et al.,
2007b). These findings suggest a possible functional effect of the
aforementioned SNPs across PON1.
Two case-control studies examined the possibility of increased ALS
susceptibility among individuals with specific PON1 polymorphisms
rendering them more vulnerable to the organophosphate-induced
neurotoxic effects (Diekstra et al., 2009; Morahan et al., 2007b). Mor-
ahan et al. examined 143 sALS cases and 143 controls. Pesticide/her-
bicide exposure was estimated according to participants' self-reports.
For the susceptibility allele, the following interactive effects were ob-
served, regarding the risk of sALS as clinical endpoint: a) for the pro-
moter polymorphisms 832 g > a,−162 g > a and−108c > t, when
the exposed to pesticides group was compared to the non-exposed
group, b) for Q192R, when the high-dose and no-exposed groups were
compared and c) for the promoter polymorphisms (909 g > c,
−832 g > a, −162 g > a and −108c > t), when the low-dose and
non-exposed groups were compared. However, no gene-environmental
interactions were revealed by the genotype or haplotype levels or when
the high-dose group was compared to the non-exposed one (with the
exception of Q192R). Hence, the authors suggested that this effect is
small and further analysis of other SNPs is of great necessity (Morahan
et al., 2007b). In the case-control models of this study, T allele of
−108c > t was overrepresented in sALS patients compared to con-
trols. Moreover, a trend towards association with promoter haplotypes
was observed. More precisely, haplotypes that decrease PON1 expres-
sion were associated with sALS, whereas haplotypes that increase PON1
expression were reported in controls (Morahan et al., 2007b). Diekstra
et al. hypothesized that ALS patients living near agricultural fields
would be more exposed to pesticides than those who live in urban
areas. Therefore, they recruited 98 ALS patients in total (49 from urban
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and 49 from rural areas) (Diekstra et al., 2009). Significant association
for L55M, (rs854560) and also a weaker signal from Q192R (rs662)
were observed. The R192/L55 haplotype was underrepresented in rural
residents (Diekstra et al., 2009). Finally, in the rural group, increased
load of M allele of L55M was associated with decreased survival
(Diekstra et al., 2009).
In contrast to the limited number of studies with gene-environment
interaction design, quite a few case-control studies have examined the
role of PON1 variants in sALS. In a study of 166 Polish Caucasians
patients with sALS, the genotype with R allele of rs662 was significantly
associated with sALS (Slowik et al., 2006). Moreover, rs854560 PON1
was found to be associated with sALS in the Irish population (Cronin
et al., 2007). Finally, in a cohort consisted of UK and US sALS patients,
rs2074351 and rs705382 as well as 5-SNP haplotypes (rs854565/
rs2299261/rs705381/rs705382/rs4141217) were associated with sALS
(Landers et al., 2008).
In contrast to the previous findings, there are also negative reports
concerning the association between the previously referred PON1
polymorphism and sALS. SNPs across PON1 failed to show evidence
about in North American, French, Canadian, Swedish, English, Italian,
Chinese, Polish, Dutch, British, German cohorts (Chen et al., 2012a;
Kasperaviciute et al., 2007; Ricci et al., 2011; Saeed et al., 2006;
Valdmanis et al., 2008; van Blitterswijk et al., 2012; Zawislak et al.,
2010). Furthermore, two meta-analyses have revealed negative results
(Lee et al., 2015; Wills et al., 2009). (Lee et al., 2015). In view of the
previous results, the role of PON1 gene in sALS remains uncertain.
However, the strongest indication exists for rs854560 (L55M),
rs662(Q192R), rs2074351 and rs705382.
Paraoxonase-2 and paraoxonase-3 genes: PON2 and PON3 enzymes
metabolize oxidized lipids and protect against lipid peroxidation. They
are not involved though in organophosphate metabolism, like PON1
enzyme (Ng et al., 2001; Reddy et al., 2001; Wills et al., 2009). The risk
alleles of the non-synonymous coding PON2 polymorphisms rs6954345
and rs12026 have been associated with lower PON activity (Cronin
et al., 2007). The possibility that individuals carrying the C allele of the
PON2 C311S polymorphism may be more susceptible to ALS was tested
in a case-control study of Polish population, revealing an association
between the C allele and sALS in dominant and additive models (Slowik
et al., 2006). However, the S allele has also been found to confer sus-
ceptibility to neurodegeneration, as the SS genotype of the S311C PON2
polymorphism (SS genotype) has been associated with the risk of AD in
a recent meta-analysis (Nie et al., 2017). Moreover, the intronic var-
iants rs10487132 (PON3) and rs11981433 (PON2), were associated
with sALS in the trio model (parents-affected child triad). Specifically,
rs10487132 was associated with sALS in 450 nuclear pedigrees, com-
prising trios and discordant sibpairs (Saeed et al., 2006). Rs10487132
(PON3) has been reported to be associated with sALS in a cohort con-
sisting of 166 Irish sALS patients and 437 controls (Cronin et al., 2007).
However, PON2 and PON3 variants failed to reach any statistical sig-
nificance in case-control models, in several cohorts (Chen et al., 2012a;
Chen et al., 2012b; Kasperaviciute et al., 2007; Ricci et al., 2011; Saeed
et al., 2006; van Blitterswijk et al., 2012). Rs978903 (PON3) and
rs11981433 (PON2) have also been meta-analyzed by Willis et al. re-
vealing negative association with ALS (Wills et al., 2009). The culture
of null hypothesis significance testing may be considered as a factor for
the lack of reproducibility of the positive results (Lash, 2017).
Haplotypes of SNPs of PON1, PON2 and PON3 have also been ex-
amined. Cronin et al. reported significant association between sALS and
the haplotype of the risk alleles of rs854560 (PON1) and rs10487132
(PON3) in an Irish population. Significant association was also reported
between sALS and the haplotype of the alleles of rs854560 (PON1),
rs705381 (PON1) and rs10487132 (PON3) (Cronin et al., 2007). Ad-
ditionally, the R-C haplotype, consisting of the R allele of rs662 (PON1)
and the C of C3111S (PON2) was overrepresented among polish sALS
patients (Slowik et al., 2006). It is possible that each SNP may confer
partial susceptibility to ALS development, possibly, under gene to gene
interaction with other polymorphisms across PON1, PON2 and PON3
genes.
Fig. 1. A. The 3D model of the normal PON1 protein;
B. The 3D model of the mutant Q192R PON1 protein;
C. The 3D model of the mutant L55M PON1 protein;
D. Parathion, diazinon and chlorpyrifos are oxidized
by liver's cytochrome P450 to their corresponding
oxons. Paraoxonase 1 (PON1) catalyzes the hydro-
lysis (detoxification) of these products, leading to the
metabolites: diethylphosphate (DEP), para-ni-
trophenol (PNP), methylpyrimidinol (MHP) and tri-
chloropyridinol (TCP). Variants across PON1 gene
influence the concentration of paraoxonase-1 en-
zyme in the serum, the protein stability and its cat-
alytic activity, resulting in defective detoxification.
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3.2. ALAD and VDR
The d-aminolevulinic acid dehydratase (ALAD) enzyme, which is
also known as porphobilinogen synthase, is mainly expressed in liver
and erythrocytes (Wetmur, 1994). The main function of this enzyme is
to catalyze the second step in heme synthesis, by adding two molecules
of aminolevulinic acid. In this way, a precursor of heme, cobalamins-
monopyrrole-porphobilinogen, is synthesized (Jaffe, 2000). The ALAD
gene seems to influence the toxicokinetics of lead. The non-synonymous
coding polymorphism, K59N (G177C), results from the substitution of G
with C dinucleotide, at the coding position 177. This leads to the con-
version of lysine (K) into asparagine (N), creating the ALAD 2 variant
allele, which is opposite to the ALAD 1 wild type allele (Wetmur, 1994).
The ALAD-2 protein has been associated with lead levels, lower in the
bones and higher in the blood (Kelada et al., 2001). Due to higher
electronegativity, it enchains lead tighter than the less electronegative
ALAD 1 protein (Bergdahl et al., 1997). This could alter the tox-
icokinetics of lead, especially among high-dose populations, leading to
longer abidance of lead in blood and tissues (Kelada et al., 2001). The
subsequent toxic effect results by two ways; either from the longer ef-
fect of lead; or from the abundant accumulation of aminolevulinic acid,
due to ALAD inhibition (Kelada et al., 2001).
Fang et al. recruited 184 ALS cases and 194 controls of US veterans
and performed a case-control study of gene-environment interaction.
They mainly focused on K59N polymorphism and blood lead levels. In
addition to blood lead measurements, the authors also measured
plasma biomarkers of bone formation [procollagen type 1 amino-
terminal peptide (PINP)] and resorption [C-terminal telopeptides of
type 1 collagen (CTX)]. No association between ALAD (ALAD2 carriers
VS ALAD1-1 homozygotes) and ALS was revealed, apart from ALAD1-1
carriers after adjustment for age and CTX (Fang et al., 2010). On the
contrary, another case-control study of gene-environment interaction,
with 109 ALS patients and 256 controls, showed a relationship between
ALS and ALAD 2 allele. Blood and bone (patella and tibia) lead levels
were measured. Specifically, the ALAD 2 allele was associated with
decreased levels of lead in patella and tibia but appeared to be un-
related to blood lead levels (Kamel et al., 2005; Kamel et al., 2003).
Moreover, the authors identified IVS2+299G > A, a previously un-
reported polymorphism at the Msp1 site in intron 2. This polymorphism
was associated with a significant decrease in bone lead levels and ALS
risk (Kamel et al., 2003).
Vitamin D may affect absorption and distribution of lead (Fullmer,
1992). The vitamin D receptor (VDR) gene encodes the vitamin D re-
ceptor protein. The BB genotype of the intronic Bsml polymorphism
between exons 8 and 9 may influence calcium absorption and dis-
tribution (Zmuda et al., 2000). Consequently, the BB genotype may
affect lead toxicity (Kamel et al., 2003). However, it is rather unlikely
that an intronic polymorphism, such as Bsml, represents a functional
loci across VDR gene (Zmuda et al., 2000). Therefore, the coexistence of
a proximal exonic SNP, high lead dose and Bsml polymorphism, may
lead to defective VDR function (Fang et al., 2010). However, Kamel
et al. reported negative results concerning Bsml and its effect on lead
levels and/or ALS development (Kamel et al., 2003).
The Fokl functional VDR polymorphism has been associated with
PD and with the cognitive decline in PD (Gatto et al., 2016; Lee et al.,
2014; Niu et al., 2015). ApaI, BsmI, and TaqI polymorphisms have not
been associated with susceptibility to PD (Lee et al., 2014; Niu et al.,
2015). Furthermore, associations between VDR polymorphisms (TaqI
and ApaI) and AD susceptibility have been reported (Laczmanski et al.,
2015; Lee et al., 2014), depending though on ethnicity and climatic
conditions (Laczmanski et al., 2015). The possible existence of gene-
environment interactions may explain, to some degree, the lack of as-
sociation (Kang et al., 2016). Therefore, despite the lack of association
between VDR SNPs and ALS, there is some indication for their con-
tribution to neurodegeneration.
3.3. SNCA
SNCA constitutes a major component of pathological features in PD
and MSA, such as Lewy bodies, neurites and glial cytoplasmic inclusions
(Mollenhauer et al., 2011; Wakabayashi et al., 1998). It is also con-
sidered to be a risk factor for these diseases (Al-Chalabi et al., 2009;
Xiromerisiou et al., 2010). There is evidence of overlapping clinical
phenotypes among PD, ALS, and MSA, suggesting that SNCA may
confer susceptibility to ALS (Guo et al., 2014). Moreover, pesticides
expedite the rate of a-syn fibrillation. PD animal models with a trans-
genic a-syn, revealed increased a-syn pathology, when exposed to
pesticides (Gao and Hong, 2011; Uversky et al., 2001). Therefore, SNCA
may influence the risk of ALS by affecting neuronal toxicity, under
combined interaction with pesticides. In total, 5 SNPs across SNCA have
been examined, up to now (rs2736990, rs356220, s3775444,
rs3822086 and rs11931074) (Guo et al., 2014) producing negative re-
sults (Chen et al., 2015; Guo et al., 2014).
Previous studies examining the interaction between REP1 SNCA
polymorphism and pesticide exposure in PD etiology, yielded little
evidence of an involvement as risk factors or as effect modifiers. These
studies though limited by small sample size or assessment of pesticide
exposure (Brighina et al., 2008; Gatto et al., 2010). Also, GG genotype
of rs10516846 across SNCA gene, may be associated with an increased
risk of AD and elevated SNCA level in CSF (Wang et al., 2016).
Therefore, the overall contribution of SNCA SNPs to neurodegeneration
seems unlikely.
3.4. MT family genes, MTF-1, GSS
Metallothioneins (MTs) are a family of metal (Cu/Zn)-binding pro-
teins. Metallothionein-I (MT-I) and metallothionein-II (MT-II) are pre-
sent in all human tissues, while Metallothionein-III (MT-III) mainly
exists in the central nervous system and metallothionein-IV in the
stratified squamous epithelia (Thirumoorthy et al., 2011). The Me-
tallothionein (MT) family is implicated in heavy metal detoxification
pathways. Lack of MT-I and MT-II is associated with increased heavy
metal toxicity (Liu et al., 1995), while overexpression of MT seems to
have a protective role (Klaassen and Liu, 1998). Deficiencies in MT
isoforms may also influence the cellular defensive mechanisms against
heavy metals, as MTs increase the cellular export and reduce the cel-
lular uptake of heavy metals. They accomplish these procedures
through sequestration of free toxic metal in the cell (Morahan et al.,
2007a). Metal transcription factor-1 (MTF-1) influences MT gene ex-
pression related to heavy metals and, consequently, the damage of
motor neurons (Gunther et al., 2012; Morahan et al., 2007c). Glu-
tathione is possibly involved in the detoxification mechanisms re-
garding pesticides and heavy metals (Abel et al., 2004; Jozefczak et al.,
2012).
One case-control study with gene-environment interaction ex-
amined the possibility that individuals carrying specific MT, MTF-1 and
GSS polymorphisms, may be more vulnerable to ALS development. The
sample consisted of 186 sALS and 186 controls with European ancestry
(Morahan et al., 2007c).MT-I Isoforms: C allele and C/C genotype of M1
isoform were reported to be more frequent in all sALS patients and even
more frequent in the male sALS subgroup. Additionally, M1C/C geno-
type was found to increase the risk of sALS, while M5 A/A genotype
revealed a protective effect. The most common haplotype, CGGGGGGG,
which was constructed by the examined MT-I SNPs, was more frequent
in the sALS group (26%) compared to controls (18%) (p=0.032). Also,
the GGAGAGGG haplotype was more frequent in controls (12%) than in
the sALS group (7%). When the M1 SNP was included in the analysis,
the haplotype difference between the groups was found to be stronger
(p=0.019 vs p=0.026). Also, the GAG haplotype of M2-M4 SNPs had
a decreased frequency in the sALS group. The subsequent analysis for
gene–environment interactions yielded negative results (Morahan et al.,
2007c). MT-IIa gene: no significant association was revealed. MTF-1
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gene: F2 MTF-1 C allele, C/C and C/T genotypes were more common in
female sALS patients but not in the total patients or in the male sALS
group, compared to controls. Only rare haplotypes (frequency < 2%)
differed significantly between patients and controls. Therefore, the
authors suggested that it is rather unlikely to expose biological effects.
GSS gene: GSS genotype–metal interactions differed between sALS pa-
tients and healthy individuals. Moreover, an association was reported
between the GCGC haplotype and sALS, when patients exposed to metal
were compared to those exposed to solvents/chemicals. Neither an as-
sociation trend nor interactions were observed for herbicide/pesticide
exposure (Morahan et al., 2007c).
Morahan et al., after the identification of eight novel SNPs in the 5′
untranslated region and in the intron 2 of MT3, performed a case-
control study. Despite the significant difference in the genotype dis-
tribution of the SNP (A1422C) between sALS and controls, the authors
suggested that this association might not be biologically relevant. They
concluded that the variants of MT3 gene are unlikely to be responsible
for susceptibility to sALS (Morahan et al., 2005; Morahan et al., 2007c).
They were also interested in examining differences in methylation le-
vels of the CpG islands of MT-Ia and MT-IIa isoforms, between sALS
patients and controls. However no significant divergence was observed
(Morahan et al., 2007a).
Hayasi et al. screened 37 Japanese sALS and 206 sex-matched
healthy controls for mutations across MT-IIA promoter and MT-III
genes. Only the novel A/G SNP (−5) on MT-IIA promoter was detected.
However, it is rather unlikely for this SNP to influence the clinical type,
the progression rate or the age of onset (Hayashi et al., 2006). Kas-
peraveciute et al. have also reported negative results, regarding the role
of MT-III gene polymorphisms in sALS (Kasperaviciute et al., 2007).
3.5. FMO
Flavin-containing monooxygenase (FMO) proteins belong to the
family of microsomal enzymes catalyzing the oxidation of several en-
dogenous and exogenous factors, including drugs (Cashman, 2000).
Additionally, yeast FMO (yFMO) is involved in redox balance, by cat-
alyzing the oxidation of biological thiols, such as the oxidation of re-
duced glutathione (GSH) to glutathione disulfide (GSSG) (Cereda et al.,
2006; Suh et al., 2000). Mutated alleles of two SNPs on the 3-UTR of
FMO gene (g. +27,568) and (g. +27,664) have been found to influence
together the sALS risk. However, interdependent action of them and the
gender specific effect cannot be excluded (Cereda et al., 2006).
3.6. SOD1, HFE, Transferrin, GSTs, PGC-1α and Nrf2
Oxidative stress contributes to the neurodegenerative process of
neurological disorders, including ALS (Cookson and Shaw, 1999;
Dardiotis et al., 2013a). Cu,Zn superoxide dismutase (SOD1) is the first
identified genetic risk factor for approximately 20% of familial and 3%
of sporadic ALS cases (Hayashi et al., 2016). Several pathophysiological
mechanisms, regarding the implication of SOD1 to ALS, have been
proposed, including oxidative stress, mitochondrial dysfunction and
excitotoxicity (Hayashi et al., 2016). Broom et al. recruited 233 sALS
cases and 248 healthy controls and genotyped them for four SNPs
(−3392, +2811, +6782, +18,636) and for deletion spanning across
SOD1 gene (Broom et al., 2004). However, they did not confirm any
connection between polymorphisms or their haplotypes and sALS sus-
ceptibility, age of onset, survival, and site of onset (Broom et al., 2004).
The G allele of the rs2070424 SOD1 polymorphism appeared to
have a protective role against AD in a Polish study (Spisak et al., 2014).
Oxidative stress is also influenced by iron accumulation. Defective
iron homeostasis is associated with oxidative damage (Wang et al.,
2004). Iron related genes may either cause or predispose to dopami-
nergic cell damage, possibly due to the contribution of iron to the
synthesis of tyrosine hydroxylase (Snyder and Connor, 2009). Muta-
tions in the Hfe gene are associated with hemochromatosis, a disease
that is characterized by iron overload (Hanson et al., 2001). Therefore,
the Hfe variants could be implicated to ALS pathophysiology, through
metal-mediated oxidative stress (Wang et al., 2004). H63D poly-
morphism across HFE gene was found to accelerate the progression of
ALS in SOD1 transgenic mice (Nandar et al., 2014). Moreover, SOD1
ALS patients, carrying the risk G allele of H63D, had a significantly
longer survival compared to those with the wild type genotype (Chio
et al., 2015). Additionally, sALS patients, homozygotes or hetero-
zygotes for H63D mutant allele, were reported to have 28.1months
longer average disease duration and 39.3% lower muscle SOD1 protein
compared to homozygotes for the wild type allele (Su et al., 2013).
Transferrin is a transmembrane iron-transport glycoprotein that binds
to iron tightly and reversibly. The rs1049296 polymorphism across
transferrin has been associated with increased PD and AD risk (Rhodes
et al., 2014; Wang et al., 2013). Transferrin also interacts with HFE
(Namekata et al., 1997). GSTO1 and 2 are members of the GST family
and they are abundant in the whole human body, but less in the brain
(Wang et al., 2005). They influence the reduction of oxidative stress,
through glutathione-dependent detoxification (Van De Giessen et al.,
2008). Rs4925 (Ala140Asp) is a functional SNP decreasing thiol-
transferase activity of the wild-type GSTO1 (Tanaka-Kagawa et al.,
2003). Several SNPs have been associated with age of fALS onset.
However, this association was evident only in a Swedish cohort. Pos-
sibly, the reported marginal trends could imply that variations across
GST genes may be phenotypically evident in certain ethnic groups (Van
De Giessen et al., 2008).
Quite a few case-control studies have been conducted examining the
role of HFE polymorphisms in sALS. Higher frequency of the mutated
allele was revealed in ALS patients than in controls. Moreover, H63D or
C282Y mutations were associated with a decrease in h-actin, a-tubulin
and Cu/Zn-SOD1 expression compared to wild types, thus indicating
alterations in axonal transport (Wang et al., 2004). H63D poly-
morphism was overrepresented in sporadic ALS individuals (Goodall
et al., 2005). Increased risk of ALS was also revealed in an Italian po-
pulation with sALS, resulting from H63D risk allele, as well as from the
combination of C282Y, H63D and S65C risk alleles (Restagno et al.,
2007). Dutch homozygotes for H63D revealed an increased risk for
developing ALS (Sutedja et al., 2007). Heterozygocity for H63D was
significantly related to sALS in a Chinese cohort (He et al., 2011). Ad-
ditionally, a lower frequency of the Y allele of C282Y was reported in a
French sALS group compared to controls (Praline et al., 2012). Carriers
of the H63D variant allele had increased risk for ALS compared to non-
carriers, but the ALS risk seems to be independent of C282Y, TfC2 and
GSTP1 mutations. Moreover, H63D was noted to affect patella and tibia
lead levels, associated with ALS. Specifically, in sALS patients, C282Y
was associated with patella and tibia lead levels, while GSTP1 was re-
lated to blood lead levels (Eum et al., 2015). Additionally, there is
strong evidence that H63D polymorphism has a protective role against
AD risk (Lin et al., 2012), while there is only mild indication that the
C282Y polymorphism protects against PD (Duan et al., 2016; Xia et al.,
2015).
Negative results have also been reported for both C282Y and H63D
(van Rheenen et al., 2013; Yen et al., 2004). Additionally, two meta-
analyses have been performed so far, concerning FHE SNPs and ALS.
The first one revealed negative correlation (van Rheenen et al., 2013).
On the contrary, the second and most recent one yielded a significant
OR for C282Y polymorphism. More precisely, C282Y was significantly
associated with decreased ALS risk, in a specific allele model (Y vs C:
OR=0.76, 95%CI=0.62–0.92, p=0.005) and also in the dominant
model of this allele (YY+CY vs CC: OR=0.75, 95%CI=0.61–0.92,
p=0.006) (Li et al., 2014). Results from pooled-analysis suggested a
positive association between ALS and H63D homozygotes, hetero-
zygotes and mutation carriers. Moreover, an association between het-
erozygosity for H63D and a higher age of onset was observed in ALS
patients (Sutedja et al., 2007).
Peroxisome proliferator-activated receptor γ coactivator 1α (PGC-
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1α), consists a transcriptional co-activator, which mainly regulates
mitochondrial biogenesis and contributes to antioxidant defense me-
chanisms (Qi et al., 2015). Gly482Ser SNP has been associated with a
decreased gene expression and a reduction in the activity of PCG-1α
(Prior et al., 2012). ALS carriers of the Gly482Ser polymorphism show
increased exercise-related oxidative stress, despite the lack of strong
evidence of association between Gly482Ser and ALS (Pasquinelli et al.,
2016). The intracellular redox balance is also influenced from the nu-
clear factor erythroid-derived 2-like 2 (NFE2L2/Nrf2) pathways.
However, −653A/G, −651G/A, and −617C/A SNPs across the Nrf2
gene promoter, which had previously been reported to have functional
significance and/or influence on basal Nrf2 expression and function,
did not reveal any association with increased ALS risk (LoGerfo et al.,
2014; Marzec et al., 2007).
3.7. Other genes
Several variants across CYP2D6 gene were reported to influence the
expression and activity of CYP2D enzyme and, consequently, the me-
tabolism of xenobiotics. Organophosphate compounds, triazine (atra-
zine), carbamates (carbaryl, maneb, ziram) and 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) are metabolized to some degree by
the cytochrome (CYP) P450 enzyme CYP2D6 (Neafsey et al., 2009;
Zhou, 2009). Rs389209 [CYP2D6*4 (G > A)] polymorphism may re-
present a variant with a significant functional effect. More specifically,
homozygotes for A allele revealed defective CYP2D6 activity, compared
to those with AG and GG genotypes. Moreover, this SNP is responsible
for aberrant mRNA splicing at intron3/exon4 boundary, causing an
early termination (Dardiotis et al., 2013b; Gough et al., 1990).
Sibbons et al. examined the following polymorphisms: CYP2D6(B)
[G to A transition], CYP2D6(A) [BP del (exon 5)], CYP2D6(T)[BP del
(exon 3)]. They detected an increased frequency of CYP2D6 (B) allele in
ALS patients (Siddons et al., 1996). Kasperveciute et al., examined quite
a few polymorphisms across CYP1A, CYP1B1, CYP2B6, CYP2C,
CYP2D6, CYP2E1 and CYP3A for possible connection with sALS. The
results of this study, however, failed to reach any statistical significant
threshold among British and German cohorts (Kasperaviciute et al.,
2007). In the same study, authors also analyzed a few additional genes
that are involved in xenobiotic metabolism pathways [PON1, PON2 and
MT3, which are described in the corresponding sections, as well as
acetylcholinesterase (ACHE), butyrylcholinesterase (BCHE), Neuro-
pathy Target Esterase (NTE), fumarylacetoacetate hydrolase (FAH),
cannabinoid receptor type 1 (CNR1), arylacetamide deacetylase-Llke 1
(AADACL1), arylformamidase (AFMID) and acylaminoacyl-peptide
hydrolase (APEH)], showing negative results (Kasperaviciute et al.,
2007).
4. Concluding remarks
Both genetic and environmental factors are supposed to increase
susceptibility to ALS development. Unfortunately, there are a relatively
small number of studies examining the interactions between genetic
and environmental factors. It is also evident that each determinant may
have a minor effect on ALS risk. In view of the former evidence, studies
estimating the combined effect and the interactions between genetic
and environmental factors are more likely to detect relevant associa-
tions, than analyze them separately.
Human genetic association studies examining the interaction be-
tween genes and pesticides or metal exposure, on the risk of ALS, have
provided remarkable results. More precisely, based on our results,
PON1 [rs854560(L55M), rs662(Q192R), rs2074351 and rs705382],
PON2 (C311S, rs11981433) and PON3 (rs10487132) seem to be the
most significant genes that are implicated in pesticides metabolism and
possibly influence ALS development. As far as the genetic variants that
are implicated in lead toxicity are concerned, the strongest indications
derived from ALAD [rs1800435 (K59N), IVS2+299G > A] and VDR
(Bsml) variants. Finally, a few evidence exist for MT-III (A1422C), MT-I
(upstream rs7403881) and GSS, which are implicated in heavy metal
detoxification pathways, as well as for HFE [rs1800562 (C282Y),
rs1799945 (H63D)] genes that possibly affect oxidative stress and,
consequently, iron accumulation. Of note, genetic association studies
examining the interaction between genes and pesticides or metal ex-
posure, have also revealed associations with other neurological diseases
(AD, PD, MS and IS). The majority of them concerned AD and PD,
suggesting an overall effect and interaction between polymorphisms
implicated in detoxification pathways and neurodegeneration.
Among the environmental toxicants, pesticides appear to be the
strongest risk factors for to ALS. Milder indications, though, exist for
heavy metals, mercury, selenium, mercury, cadmium, iron, lead and
xenobiotics. Therefore, both toxicants themselves, and genetic varia-
bility that influences these metabolic pathways, appear to interact to
increase susceptibility for ALS. However, studies examining the role of
both toxicants and genetic variability as ALS risk factors, and their in-
teractions, are relatively few. In view of the former considerations,
definitive conclusions whether toxicants are the primary cause and the
genes are additional factors for ALS development, or vice versa, cannot
be drawn so far.
It has been indicated that genetic susceptibility, either in pesticide
metabolism or in heavy metal detoxification pathways and tox-
icokinetics of lead, may increase the risk of ALS development. However,
this indication is limited and uncertain at the present. The culture of
null hypothesis significance testing may be considered as a factor for
the lack of reproducibility of the positive results (Lash, 2017). By cor-
rect use and interpretation of statistical value, the misinterpretation of
p-values, confidence intervals and statistical tests in general, could be
avoided (Greenland, 2017). The scientific reasoning could not be sub-
stitute from single statistical value, index or test (Rothman, 2016;
Wasserstein and Lazar, 2016). Therefore, it is of great necessity more
studies with gene-environment interaction design, and studies in-
vestigating the etiologic role of assuming both environmental and ge-
netic factors have to be conducted in the future, in order for the pa-
thogenic mechanisms of ALS to be elucidated.
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